Rain Oncology Inc
RAIN
Get informed when a big investor buys or sells
+ FollowMarket Cap$15.69M
Close$
$-1.23
164.3% downside
Current Fair Value
164.3% downsideOvervalued by 164.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $15.69 Million |
|---|---|
| Enterprise Value | $15.11 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.2 |
| Beta | -0.27 |
| Outstanding Shares | 7,829,921 |
Return
| Return on Equity | 66.00% |
|---|---|
| Return on Assets | -360.68% |
| Return on Invested Capital | 62.49% |
Valuation & Multiples
| P/E Ratio | -1.57 |
|---|---|
| PEG | -6.16 |
| Price to Sales | - |
| Price to Book Ratio | -0.96 |
| Enterprise Value to Revenue | 1439.27 |
| Enterprise Value to EBIT | -1.82 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 12.89%▲ 4.68% |
|---|---|
| Total Invested | $2.44M▼ 29.92% |
| Investors Holding | 17▲ 4.00% |
ESG Score
No data
About Rain Therapeutics Inc
Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes usi...